Literature DB >> 12858191

Bacterial virus phi29 pRNA as a hammerhead ribozyme escort to destroy hepatitis B virus.

S Hoeprich1, Q Zhou, S Guo, D Shu, G Qi, Y Wang, P Guo.   

Abstract

The DNA-packaging pRNA of bacterial virus phi29, which forms dimers and then hexamers, contains two independent tightly self-folded domains. Circularly permuted pRNAs were constructed without impacting pRNA folding. Connecting the pRNA 5'/3' ends with variable sequences did not disturb its folding and function. These unique features, which help prevent two common problems - exonuclease degradation and misfolding in the cell, make pRNA an ideal vector to carry therapeutic RNAs. A pRNA-based vector was designed to carry hammerhead ribozymes that cleave the hepatitis B virus (HBV) polyA signal. The chimeric HBV-targeting ribozyme was connected to the pRNA 5'/3' ends as circularly permuted pRNA. Two cis-cleaving ribozymes were used to flank and process the chimeric ribozyme. The hammerhead ribozyme including its two arms for HBV targeting was able to fold correctly while escorted by the pRNA. The chimeric ribozyme cleaved the polyA signal of HBV mRNA in vitro almost completely. Cell culture studies showed that the chimeric ribozyme was able to enhance the inhibition of HBV replication when compared with the ribozyme not escorted by pRNA, as demonstrated by Northern blot and e-antigen assays. pRNA could also carry another hammerhead ribozyme to cleave other RNA substrate. These findings suggest that pRNA can be used as a vector for imparting stability to ribozymes, antisense, and other therapeutic RNA molecules in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12858191     DOI: 10.1038/sj.gt.3302002

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  48 in total

1.  AIDS treatment with novel anti-HIV compounds improved by nanotechnology.

Authors:  Xiaowei Ma; Dongliang Wang; Yan Wu; Rodney J Y Ho; Lee Jia; Peixuan Guo; Liming Hu; Gengmei Xing; Yi Zeng; Xing-Jie Liang
Journal:  AAPS J       Date:  2010-04-06       Impact factor: 4.009

Review 2.  Gene therapeutic approaches to inhibit hepatitis B virus replication.

Authors:  Maren Gebbing; Thorsten Bergmann; Eric Schulz; Anja Ehrhardt
Journal:  World J Hepatol       Date:  2015-02-27

3.  Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology.

Authors:  Annette Khaled; Songchuan Guo; Feng Li; Peixuan Guo
Journal:  Nano Lett       Date:  2005-09       Impact factor: 11.189

4.  Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA.

Authors:  Songchuan Guo; Nuska Tschammer; Sulma Mohammed; Peixuan Guo
Journal:  Hum Gene Ther       Date:  2005-09       Impact factor: 5.695

Review 5.  RNA nanotechnology: engineering, assembly and applications in detection, gene delivery and therapy.

Authors:  Peixuan Guo
Journal:  J Nanosci Nanotechnol       Date:  2005-12

6.  RNA nanotechnology for computer design and in vivo computation.

Authors:  Meikang Qiu; Emil Khisamutdinov; Zhengyi Zhao; Cheryl Pan; Jeong-Woo Choi; Neocles B Leontis; Peixuan Guo
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2013-09-02       Impact factor: 4.226

7.  Fluorogenic RNA nanoparticles for monitoring RNA folding and degradation in real time in living cells.

Authors:  Randall Reif; Farzin Haque; Peixuan Guo
Journal:  Nucleic Acid Ther       Date:  2012-10-31       Impact factor: 5.486

8.  Nucleic acid-based nanoengineering: novel structures for biomedical applications.

Authors:  Hanying Li; Thomas H Labean; Kam W Leong
Journal:  Interface Focus       Date:  2011-06-28       Impact factor: 3.906

9.  Square-shaped RNA particles from different RNA folds.

Authors:  Isil Severcan; Cody Geary; Erik Verzemnieks; Arkadiusz Chworos; Luc Jaeger
Journal:  Nano Lett       Date:  2009-03       Impact factor: 11.189

Review 10.  Engineering RNA for targeted siRNA delivery and medical application.

Authors:  Peixuan Guo; Oana Coban; Nicholas M Snead; Joe Trebley; Steve Hoeprich; Songchuan Guo; Yi Shu
Journal:  Adv Drug Deliv Rev       Date:  2010-03-15       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.